



Health Insurance (Section 3C Co-Dependent Pathology Services) Amendment Determination (No. 7) 2020

I, Paul McBride, delegate of the Minister for Health, make the following Determination.

Dated 17 December 2020

Paul McBride
First Assistant Secretary
Medical Benefits Division
Health Resourcing Group
Department of Health

Contents

1 Name.....	1
2 Commencement	1
3 Authority.....	1
4 Schedules	1
Schedule 1— Amendments	2
<i>Health Insurance (Section 3C Co-Dependent Pathology Services) Determination 2018</i>	2

1 Name

This instrument is the *Health Insurance (Section 3C Co-Dependent Pathology Services) Amendment Determination (No. 7) 2020*.

2 Commencement

- (1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information		
Column 1	Column 2	Column 3
Provisions	Commencement	Date/Details
1. The whole of this instrument	1 January 2021	

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

- (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

This instrument is made under subsection 3C(1) of the *Health Insurance Act 1973*.

4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1— Amendments

Health Insurance (Section 3C Co-Dependent Pathology Services) Determination 2018

1 Schedule 1 (cell at item 73337, column 2)

Repeal the cell, substitute:

A test of tumour tissue from a patient diagnosed with non-small cell lung cancer, shown to have non-squamous histology or histology not otherwise specified, requested by, or on behalf of, a specialist or consultant physician, to determine if the requirements relating to epidermal growth factor receptor (EGFR) gene status for access to an EGFR tyrosine kinase inhibitor listed under the Pharmaceutical Benefits Scheme (PBS) are fulfilled